- Home
- SEED vs INKT Comparison
SEED vs INKT Comparison
Compare SEED & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | INKT |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 51.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SEED | INKT |
|---|---|---|
| Price | $1.32 | $11.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 26.2K | 12.8K |
| Earning Date | 02-09-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,910,081.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $4.56 |
| 52 Week High | $2.70 | $76.00 |
Technical Indicators
Market Signals| Indicator | SEED | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 51.03 |
| Support Level | $1.12 | $11.28 |
| Resistance Level | $1.20 | $12.31 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 85.19 | 67.21 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.